Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marvin Meadors

Rheumatology Nashville, TN Medical Doctor

NPI 1518952852 CMS profile 205254

4230 Harding Pike Ste 501, Nashville, TN 37205

Open in the dashboard

General payments

$5,746

332 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marvin Meadors of Nashville, TN is reported in the CMS Open Payments database as having received $5,746 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $100 1
2024 General $99 1
2022 General $259 12
2021 General $2,071 114
2020 General $1,441 86
2019 General $1,776 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marvin Meadors
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Marvin Meadors were reported at $100. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Marvin Meadors Rheumatology median Middle half National median
2019 $1,776 $744 $153–$2,687 $163
2020 $1,441 $462 $98–$2,027 $114
2021 $2,071 $531 $101–$2,153 $132
2022 $259 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $99 $830 $166–$2,660 $164
2025 $100 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,286 75 payments
  2. AbbVie, Inc. $642 38 payments
  3. UCB, Inc. $509 23 payments
  4. Novartis Pharmaceuticals Corporation $492 32 payments
  5. Janssen Biotech, Inc. $392 21 payments
  6. GlaxoSmithKline, LLC. $339 19 payments
  7. Lilly USA, LLC $304 22 payments
  8. E.R. Squibb & Sons, L.L.C. $243 19 payments
  9. Pfizer Inc. $204 11 payments
  10. Mallinckrodt Hospital Products Inc. $172 7 payments
  11. Other $1,161 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,590 327 payments
  2. Education $156 5 payments
Products named General payments · program years 2019–2025
  1. Prolia $600 35 payments
  2. COSENTYX $492 32 payments
  3. Cimzia $409 22 payments
  4. HUMIRA $341 22 payments
  5. BENLYSTA $339 19 payments
  6. Enbrel Inflammation $324 17 payments
  7. EVENITY $291 17 payments
  8. SIMPONI ARIA $283 19 payments
  9. TALTZ $283 21 payments
  10. Enbrel Inflammation $281 19 payments
  11. Other $3,603 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

4,269

Median for Rheumatology: 1,511

Drug cost

$1,490,943

Median for Rheumatology: $1,139,948

Branded share of claims

25%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Xr Tofacitinib Citrate Brand 117 $693,620
Enbrel Etanercept Brand 22 $278,720
Humira(Cf) Pen Adalimumab Brand 16 $161,655
Rinvoq Upadacitinib Brand 14 $116,095
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $99,576
Otezla Apremilast Brand 11 $54,437
Methotrexate Methotrexate Sodium Brand 532 $15,901
Hydroxychloroquine Sulfate Generic 319 $12,651
Prednisone Generic 928 $9,941
Febuxostat Generic 22 $7,422

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$543,609

Of which drugs: $408,876

Medicare patients

431

Average age 75

Services billed

40,203

324 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 30%
Ischemic heart disease 28%
Diabetes 26%
Chronic kidney disease 24%
Depression 23%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 18 1,920 $38,001
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,398
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 11 384 $87

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record